Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Conditions › Myelodysplastic Syndrome

Myelodysplastic Syndrome

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Donor-derived anti-CD33 CAR T-cell therapy showed 20% overall response in 15 adults with relapsed AML/MDS.
Oncology Phase I
Donor-derived anti-CD33 CAR T-cell therapy showed 20% overall response in 15 adults with relapsed AML/MDS. Donor-Derived Cells Show Promise Against Leukemia Relapse
This Phase 1/2 study enrolled 15 adults with relapsed or MRD-positive CD33+ AML/MDS after allogeneic hematopoietic cell transplantation. Don…
A new treatment using donor immune cells shows early signs of fighting leukemia after transplant.
Blood Apr 24, 2026
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Oncology Phase II
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
CT.gov Apr 13, 2026